CDD3505 is primarily utilized in the field of oncology research, where it serves as a potent inhibitor targeting specific cellular pathways involved in cancer progression. Its application is significant in preclinical studies aimed at understanding tumor growth mechanisms and evaluating the efficacy of novel therapeutic strategies. Researchers employ CDD3505 to investigate its potential in suppressing tumor cell proliferation and inducing apoptosis, particularly in cancers resistant to conventional treatments. Additionally, it is used in combination therapy studies to explore synergistic effects with other anticancer agents, potentially enhancing treatment outcomes. Its role in molecular biology also extends to elucidating signaling pathways, contributing to the development of targeted cancer therapies.